SEC Form 4 · accession 0001209191-18-007403
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Davidson
Officer — Chief Medical Officer
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 4:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 1, 2018 | A | 11,250 | $0.00 | A | 24,905 | D | |
| Common Stock | Feb 2, 2018 | M | 4,000 | $5.5004 | A | 28,905 | D | |
| Common StockF3 | Feb 2, 2018 | S | 2,600 | $201.9065 | D | 26,305 | D | |
| Common StockF4 | Feb 2, 2018 | S | 1,400 | $203.2032 | D | 24,905 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $205.25 | Feb 1, 2018 | A | 45,000 | A | — | Feb 1, 2028 | Common Stock | 45,000 | 45,000 | D |
| Stock Option (right to buy)F6 | $5.5004 | Feb 2, 2018 | M | 4,000 | D | — | Jan 16, 2023 | Common Stock | 4,000 | 67,951 | D |
Explanation of responses
- F1Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2019, 25% on 01/04/2020, 25% on 01/04/2021, and 25% on 01/04/2022.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.
- F3The range of prices for the transaction reported on this line was $201.55 to $202.45. The average weighted price was $201.9065. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The range of prices for the transaction reported on this line was $202.95 to $203.50. The average weighted price was $203.2032. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2019, and in 36 equal monthly installments.
- F6This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.